Zoetis

YTD

ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments.

CEO

Kristin C. Peck

CEOKristin C. Peck

Employees

14,500

Employees14,500

Headquarters

Parsippany, New Jersey

HeadquartersParsippany, New Jersey

Founded

1952

Founded1952

Employees

14,500

Employees14,500

ZTS Key Statistics

Market cap

51.89B

Market cap51.89B

Price-Earnings ratio

20.32

Price-Earnings ratio20.32

Dividend yield

1.66%

Dividend yield1.66%

Average volume

3.01M

Average volume3.01M

High today

$123.29

High today$123.29

Low today

$120.55

Low today$120.55

Open price

$122.35

Open price$122.35

Volume

2.11M

Volume2.11M

52 Week high

$172.23

52 Week high$172.23

52 Week low

$113.29

52 Week low$113.29

Stock Snapshot

As of today, Zoetis(ZTS) shares are valued at $122.92. The company's market cap stands at 51.89B, with a P/E ratio of 20.32 and a dividend yield of 1.7%.

On 2026-04-20, Zoetis(ZTS) stock moved within a range of $120.55 to $123.29. With shares now at $122.92, the stock is trading +2.0% above its intraday low and -0.3% below the session's peak.

Trading volume for Zoetis(ZTS) stock has reached 2.11M, versus its average volume of 3.01M.

Over the past 52 weeks, Zoetis(ZTS) stock has traded between a high of $172.23 and a low of $113.29.

ZTS News

Simply Wall St 2d

How Investors Are Reacting To Zoetis Governance Stance Amid Optimistic Q1 2026 Earnings Expectations

Zoetis Inc. recently opposed a shareholder proposal on written-consent rights in its definitive proxy filing, even as CEO Kristin C. Peck highlighted the compan...

Simply Wall St 3d

Assessing Zoetis Valuation After Citi’s Fresh Buy Rating And Osteoarthritis Drug Focus

Advertisement Why Citi’s fresh coverage puts Zoetis (ZTS) back in focus Citi’s new coverage of Zoetis (ZTS), centered on upcoming long acting osteoarthritis d...

Nasdaq 4d

Ex-Div Reminder for Zoetis

Looking at the universe of stocks we cover at Dividend Channel , on 4/20/26, Zoetis Inc (Symbol: ZTS) will trade ex-dividend, for its quarterly dividend of $0.5...

Analyst ratings

63%

of 24 ratings

Buy

62.5%

Hold

37.5%

Sell

More ZTS News

TipRanks 5d

Zoetis initiated with a Buy at Citi

Citi initiated coverage of Zoetis (ZTS) with a Buy rating and $145 price target Citi also opened an “upside 90-day catalyst watch” on Zoetis, saying Solensia wi...

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.